Relationships between kallikrein secretion, kallikrein excretion and beta-adrenoceptors in kidney cortical slices from neurogenic hypertensive dogs.
1. Sinoaortic denervation (SAD) in dogs is characterized by an increase in blood pressure and heart rate as well as the development of renal morphological lesions similar to those observed in essential hypertension in human subjects. To assess the effect of SAD on the secretion of kallikrein kinin systems (KKS), we studied the in vitro secretion of kallikrein by renal cortical slices of normal and neurogenic hypertensive dogs (1 and 18 months after SAD). The method using renal cortical slices allowed the study of secretion of kallikrein independently of renal perfusion pressure. The number of renal beta-adrenoceptors was measured by [125I]-cyanopindolol binding. 2. SAD was associated with a marked increase in urinary kallikrein excretion at one month and a significant decrease at 18 months when compared with controls. Both changes were statistically significant (P < 0.05). Concurrently, a progressive increase in in vitro kallikrein secretion was observed (+80 +/- 10% and +179 +/- 48%, 1 and 18 months after SAD, respectively). Moreover, the cortical slices obtained from sinoaortic denervated dogs contained more kallikrein than the control cortical slices (+32 +/- 16% and +55 +/- 7%, 1 and 18 months after SAD, respectively). 3. Renal beta-adrenoceptor number significantly (P < 0.05) decreased 18 months after SAD from 18 +/- 2 to 8 +/- 3 fmol mg-1 protein without any change in affinity constant. 4. Although there was no test of association, because the number of renal beta-adrenoceptors decreased whereas kallikrein secretion increased, the present data could suggest a beta-adrenoceptor-mediated inhibition of kallikrein secretion. These results show that although the urinary kallikrein is decreased, the tissue secretory capacities are enhanced. This could suggest a renal compensatory mechanism possibly involved in tissue protection in dogs after SAD, although such a mechanism is not sufficient to reverse hypertension.
Damase-Michel
C
C
Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Toulouse, France.
Bompart
G
G
Durrieu
G
G
Montastruc
J L
JL
Montastruc
P
P
Girolami
J P
JP
D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D002395:Catecholamines / Q000097:blood; D003714:Denervation; D004195:Disease Models, Animal; D004285:Dogs; D006339:Heart Rate / Q000502:physiology; D006973:Hypertension / Q000503:physiopathology* / Q000652:urine*; D007610:Kallikreins / Q000378:metabolism* / Q000652:urine*; D007672:Kidney Cortex / Q000378:metabolism / Q000503:physiopathology* / Q000648:ultrastructure*; D008297:Male; D011507:Proteinuria / Q000652:urine; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D012850:Sinus of Valsalva / Q000294:innervation
D002395:Catecholamines; D011943:Receptors, Adrenergic, beta; D007610:Kallikreins